These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 34617381)

  • 1. Effects of sodium-glucose cotransporter 2 inhibitors on serum uric acid in patients with type 2 diabetes mellitus: A systematic review and network meta-analysis.
    Hu X; Yang Y; Hu X; Jia X; Liu H; Wei M; Lyu Z
    Diabetes Obes Metab; 2022 Feb; 24(2):228-238. PubMed ID: 34617381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: A meta-analysis of randomized controlled trials.
    Zhao Y; Xu L; Tian D; Xia P; Zheng H; Wang L; Chen L
    Diabetes Obes Metab; 2018 Feb; 20(2):458-462. PubMed ID: 28846182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative safety of different sodium-glucose transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trials.
    Li CX; Liu LY; Zhang CX; Geng XH; Gu SM; Wang YQ; Liu H; Xie Q; Liang S
    Front Endocrinol (Lausanne); 2023; 14():1238399. PubMed ID: 37701900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impacts of Sodium/Glucose Cotransporter-2 Inhibitors on Circulating Uric Acid Concentrations: A Systematic Review and Meta-Analysis.
    Akbari A; Rafiee M; Sathyapalan T; Sahebkar A
    J Diabetes Res; 2022; 2022():7520632. PubMed ID: 35224108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative safety of different recommended doses of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis of randomized clinical trials.
    Chen L; Xue Q; Yan C; Tang B; Wang L; Zhang B; Zhao Q
    Front Endocrinol (Lausanne); 2023; 14():1256548. PubMed ID: 38027214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of sodium-glucose cotransporter-2 (SGLT-2) inhibitors on serum uric acid levels in patients with chronic kidney disease: a systematic review and network meta-analysis.
    Zhang L; Zhang F; Bai Y; Huang L; Zhong Y; Zhang X
    BMJ Open Diabetes Res Care; 2024 Jan; 12(1):. PubMed ID: 38238025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum uric acid lowering and effects of sodium-glucose cotransporter-2 inhibitors on gout: A meta-analysis and meta-regression of randomized controlled trials.
    Banerjee M; Pal R; Maisnam I; Chowdhury S; Mukhopadhyay S
    Diabetes Obes Metab; 2023 Sep; 25(9):2697-2703. PubMed ID: 37334516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sodium-Glucose Cotransporter-2 (SGLT-2) Attenuates Serum Uric Acid (SUA) Level in Patients with Type 2 Diabetes.
    Hussain M; Elahi A; Hussain A; Iqbal J; Akhtar L; Majid A
    J Diabetes Res; 2021; 2021():9973862. PubMed ID: 34239940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective sodium-glucose cotransporter-2 inhibitors in the improvement of hemoglobin and hematocrit in patients with type 2 diabetes mellitus: a network meta-analysis.
    Luo Y; Bai R; Zhang W; Qin G
    Front Endocrinol (Lausanne); 2024; 15():1333624. PubMed ID: 38362282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors and Combined SGLT1/2 Inhibitors on Cardiovascular, Metabolic, Renal, and Safety Outcomes in Patients with Diabetes: A Network Meta-Analysis of 111 Randomized Controlled Trials.
    Teo YN; Ting AZH; Teo YH; Chong EY; Tan JTA; Syn NL; Chia AZQ; Ong HT; Cheong AJY; Li TY; Poh KK; Yeo TC; Chan MY; Wong RCC; Chai P; Sia CH
    Am J Cardiovasc Drugs; 2022 May; 22(3):299-323. PubMed ID: 35316484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of Sodium-Glucose Cotransporter-2 Inhibitors on Plasma Adiponectin in Patients with Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials.
    Wang Y; Xia N
    Horm Metab Res; 2022 Dec; 54(12):833-844. PubMed ID: 36049756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study.
    Kosiborod M; Lam CSP; Kohsaka S; Kim DJ; Karasik A; Shaw J; Tangri N; Goh SY; Thuresson M; Chen H; Surmont F; Hammar N; Fenici P;
    J Am Coll Cardiol; 2018 Jun; 71(23):2628-2639. PubMed ID: 29540325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of sodium glucose cotransporter-2 inhibitors on serum uric acid in type 2 diabetes mellitus: A systematic review with an indirect comparison meta-analysis.
    Xin Y; Guo Y; Li Y; Ma Y; Li L; Jiang H
    Saudi J Biol Sci; 2019 Feb; 26(2):421-426. PubMed ID: 31485187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring the comparative cardiovascular death benefits of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes: a frequentist and Bayesian network meta-analysis-based scoring.
    Ghosal S; Sinha B
    Front Endocrinol (Lausanne); 2023; 14():1168755. PubMed ID: 37469980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Weight in Type 2 Diabetes Mellitus and Therapeutic Regimen Recommendation.
    Wang DD; Mao YZ; Yang Y; Wang TY; Zhu P; He SM; Chen X
    J Diabetes Res; 2022; 2022():4491900. PubMed ID: 35342769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative efficacy and safety of sodium-glucose cotransporter 2 inhibitors for renal outcomes in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis.
    Ma J; Lu J; Shen P; Zhao X; Zhu H
    Ren Fail; 2023; 45(2):2222847. PubMed ID: 37724571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.
    Palmer SC; Tendal B; Mustafa RA; Vandvik PO; Li S; Hao Q; Tunnicliffe D; Ruospo M; Natale P; Saglimbene V; Nicolucci A; Johnson DW; Tonelli M; Rossi MC; Badve SV; Cho Y; Nadeau-Fredette AC; Burke M; Faruque LI; Lloyd A; Ahmad N; Liu Y; Tiv S; Millard T; Gagliardi L; Kolanu N; Barmanray RD; McMorrow R; Raygoza Cortez AK; White H; Chen X; Zhou X; Liu J; Rodríguez AF; González-Colmenero AD; Wang Y; Li L; Sutanto S; Solis RC; Díaz González-Colmenero F; Rodriguez-Gutierrez R; Walsh M; Guyatt G; Strippoli GFM
    BMJ; 2021 Jan; 372():m4573. PubMed ID: 33441402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of effects of SGLT-2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in type 2 diabetes mellitus patients with/without albuminuria: A systematic review and network meta-analysis.
    Kawai Y; Uneda K; Yamada T; Kinguchi S; Kobayashi K; Azushima K; Kanaoka T; Toya Y; Wakui H; Tamura K
    Diabetes Res Clin Pract; 2022 Jan; 183():109146. PubMed ID: 34780865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sodium-glucose cotransporter 2 inhibitors and fracture risk in patients with type 2 diabetes mellitus: A systematic literature review and Bayesian network meta-analysis of randomized controlled trials.
    Azharuddin M; Adil M; Ghosh P; Sharma M
    Diabetes Res Clin Pract; 2018 Dec; 146():180-190. PubMed ID: 30389620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal protective effect and safety of sodium-glucose cotransporter-2 inhibitors in patients with chronic kidney disease and type 2 diabetes mellitus: a network meta-analysis and systematic review.
    Lin J; Wang S; Wen T; Zhang X
    Int Urol Nephrol; 2022 Sep; 54(9):2305-2316. PubMed ID: 35133574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.